Quest Diagnostics (DGX) Tops Q2 EPS by 30c; updates guidance

Quest Diagnostics (NYSE: DGX) reported Q2 EPS of $3.12, $0.30 better than the analyst estimate of $2.82. Revenue for the quarter came in at $3.04 billion versus the consensus estimate of $2.97 billion.

GUIDANCE:

Quest Diagnostics sees FY2026 EPS of $11.05-$11.25, versus the consensus of $10.77. Quest Diagnostics sees FY2026 revenue of $11.95-12.05 billion, versus the consensus of $11.853 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• Medtronic jumps on earnings beat and raised guidance
• Humana reaffirms 2026 earnings guidance ahead of investor meetings
• Butterfly Network and Merge Labs sign BCI ultrasound licensing deal